pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid has been researched along with Anoxia-Ischemia, Brain in 1 studies
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xiao, J | 1 |
| Huang, Y | 1 |
| Li, X | 1 |
| Li, L | 1 |
| Yang, T | 1 |
| Huang, L | 1 |
| Yang, L | 1 |
| Jiang, H | 1 |
| Li, H | 1 |
| Li, F | 1 |
1 other study available for pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Anoxia-Ischemia, Brain
| Article | Year |
|---|---|
TNP-ATP is Beneficial for Treatment of Neonatal Hypoxia-Induced Hypomyelination and Cognitive Decline.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Brain; Cognition Disorders; Disease Models, Anima | 2016 |